Nanobiotix (NBTX) Competitors $5.01 +0.28 (+5.92%) Closing price 07/3/2025 03:29 PM EasternExtended Trading$5.08 +0.08 (+1.50%) As of 07/3/2025 04:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NBTX vs. LENZ, CRMD, OCS, RCUS, AVXL, COGT, CMRX, CDMO, AVBP, and SNDXShould you be buying Nanobiotix stock or one of its competitors? The main competitors of Nanobiotix include LENZ Therapeutics (LENZ), CorMedix (CRMD), Oculis (OCS), Arcus Biosciences (RCUS), Anavex Life Sciences (AVXL), Cogent Biosciences (COGT), Chimerix (CMRX), Avid Bioservices (CDMO), ArriVent BioPharma (AVBP), and Syndax Pharmaceuticals (SNDX). These companies are all part of the "pharmaceutical products" industry. Nanobiotix vs. Its Competitors LENZ Therapeutics CorMedix Oculis Arcus Biosciences Anavex Life Sciences Cogent Biosciences Chimerix Avid Bioservices ArriVent BioPharma Syndax Pharmaceuticals Nanobiotix (NASDAQ:NBTX) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment. Which has more risk & volatility, NBTX or LENZ? Nanobiotix has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500. Which has stronger valuation & earnings, NBTX or LENZ? LENZ Therapeutics has lower revenue, but higher earnings than Nanobiotix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNanobiotix$39.18M6.03-$73.73MN/AN/ALENZ TherapeuticsN/AN/A-$49.77M-$1.77-18.38 Does the media favor NBTX or LENZ? In the previous week, LENZ Therapeutics had 3 more articles in the media than Nanobiotix. MarketBeat recorded 3 mentions for LENZ Therapeutics and 0 mentions for Nanobiotix. LENZ Therapeutics' average media sentiment score of 0.93 beat Nanobiotix's score of 0.00 indicating that LENZ Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Nanobiotix Neutral LENZ Therapeutics Positive Do analysts rate NBTX or LENZ? Nanobiotix currently has a consensus price target of $8.00, indicating a potential upside of 59.68%. LENZ Therapeutics has a consensus price target of $46.60, indicating a potential upside of 43.23%. Given Nanobiotix's higher probable upside, equities analysts plainly believe Nanobiotix is more favorable than LENZ Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nanobiotix 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50LENZ Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Do insiders & institutionals believe in NBTX or LENZ? 38.8% of Nanobiotix shares are held by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are held by institutional investors. 3.5% of Nanobiotix shares are held by insiders. Comparatively, 6.9% of LENZ Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is NBTX or LENZ more profitable? Nanobiotix's return on equity of 0.00% beat LENZ Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets NanobiotixN/A N/A N/A LENZ Therapeutics N/A -23.74%-22.65% SummaryLENZ Therapeutics beats Nanobiotix on 9 of the 13 factors compared between the two stocks. Get Nanobiotix News Delivered to You Automatically Sign up to receive the latest news and ratings for NBTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBTX vs. The Competition Export to ExcelMetricNanobiotixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$229.54M$2.43B$5.56B$9.05BDividend YieldN/A1.78%5.24%3.99%P/E RatioN/A9.0227.6520.23Price / Sales6.03680.43419.56119.26Price / CashN/A21.7726.2128.59Price / Book-3.324.558.035.65Net Income-$73.73M$31.26M$3.18B$249.15M7 Day Performance8.68%3.25%2.93%3.28%1 Month Performance6.37%3.46%1.72%3.95%1 Year Performance-8.24%0.77%34.39%20.98% Nanobiotix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBTXNanobiotix1.6861 of 5 stars$5.01+5.9%$8.00+59.7%-8.2%$229.54M$39.18M0.00100Positive NewsGap UpLENZLENZ Therapeutics1.3424 of 5 stars$29.31-2.9%$46.60+59.0%+80.2%$849.45MN/A-16.56110CRMDCorMedix2.5782 of 5 stars$12.32-1.4%$17.14+39.1%+182.5%$847.81M$43.47M56.0030Analyst RevisionHigh Trading VolumeOCSOculis1.7287 of 5 stars$19.41+0.3%$35.33+82.0%+62.6%$844.87M$780K-7.352News CoverageRCUSArcus Biosciences2.774 of 5 stars$8.17+2.8%$21.29+160.5%-40.0%$841.79M$258M-1.95500AVXLAnavex Life Sciences3.6022 of 5 stars$9.22-2.7%$44.00+377.2%+155.8%$809.33MN/A-16.7640Positive NewsCOGTCogent Biosciences2.5922 of 5 stars$7.18+1.1%$14.43+101.0%-9.8%$808.38MN/A-3.9080News CoverageAnalyst RevisionCMRXChimerix0.6197 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212K-9.0990CDMOAvid Bioservices0.6863 of 5 stars$12.50+0.1%$12.25-2.0%+68.4%$799.18M$139.91M-5.23320High Trading VolumeAVBPArriVent BioPharma1.7389 of 5 stars$21.77-5.0%$40.00+83.7%+11.6%$783.81MN/A-5.7740SNDXSyndax Pharmaceuticals3.1224 of 5 stars$9.36+3.5%$35.80+282.5%-55.7%$777.87M$23.68M-2.42110 Related Companies and Tools Related Companies LENZ Therapeutics Competitors CorMedix Competitors Oculis Competitors Arcus Biosciences Competitors Anavex Life Sciences Competitors Cogent Biosciences Competitors Chimerix Competitors Avid Bioservices Competitors ArriVent BioPharma Competitors Syndax Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NBTX) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nanobiotix S.A. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Nanobiotix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
